¡Ya estamos en ! Descubre más

Quantum-Si Incorporated

QSI

Capitalización de mercado USD 245 M

1.12 USD

-0.19

14.5%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

1.11

-0.01

0.89%

1 día

-14.5%

5 días

-24.32%

1 mes

53.4%

3 meses

36.7%

6 meses

7.69%

En lo que va del año

-3.45%

1 año

-55.91%

5 años

-86.31%

10 años

-88.66%

Acerca de: Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

Empleados: 145

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 81.3%

Negativo 18.8%

Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026

BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026.

Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026

Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1).

Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

Leading Indicators For The October Breakout Cycle

Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.

Leading Indicators For The October Breakout Cycle

Beyond Elon Musk's Neuralink: Two Public Stocks With a Stake in the Brain Race

Elon Musk's Neuralink is giving us a glimpse of a future in which the human brain can communicate directly with computers. For investors, there's just one problem: You can't buy Neuralink stock.

Beyond Elon Musk's Neuralink: Two Public Stocks With a Stake in the Brain Race

Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program

BRANFORD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated detection of 19 amino acids in its Proteus™ development program and is now working to deploy that capability into a developmental sequencing kit for routine use on integrated Proteus instruments.

Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program

Top 3 Health Care Stocks That May Collapse In Q4

As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q4

Schaeffers Research

3 Biotech Stocks Put Traders Are Targeting Today

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.

3 Biotech Stocks Put Traders Are Targeting Today

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum® Pro instrument.

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments.

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities

BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market education on its Proteus platform and applications for protein sequencing.

Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™